Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-019-56481-0 http://scihub22266oqcxt.onion/10.1038/s41598-019-56481-0 31882748!6934550!31882748     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2019 ; 9 (1): 20199 Nephropedia Template TP {{tp|p=31882748|t=2019. In Vivo Activity of Amodiaquine against Ebola Virus Infection |pdf=|usr=}}{{31882748}} gab.com Text In Vivo Activity of Amodiaquine against Ebola Virus Infection JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=31882748 #FOAvip During the Ebola virus disease (EVD) epidemic in Western Africa (2013?2016), antimalarial treatment was administered to EVD patients due to the high coexisting malaria burden in accordance with World Health Organization guidelines. In an Ebola treatment center in Liberia, EVD patients receiving the combination antimalarial artesunate-amodiaquine had a lower risk of death compared to those treated with artemether-lumefantrine. As artemether and artesunate are derivatives of artemisinin, the beneficial anti-Ebola virus (EBOV) effect observed could possibly be attributed to the change from lumefantrine to amodiaquine. Amodiaquine is a widely used antimalarial in the countries that experience outbreaks of EVD and, therefore, holds promise as an approved drug that could be repurposed for treating EBOV infections. We investigated the potential anti-EBOV effect of amodiaquine in a well-characterized nonhuman primate model of EVD. Using a similar 3-day antimalarial dosing strategy as for human patients, plasma concentrations of amodiaquine in healthy animals were similar to those found in humans. However, the treatment regimen did not result in a survival benefit or decrease of disease signs in EBOV-infected animals. While amodiaquine on its own failed to demonstrate efficacy, we cannot exclude potential therapeutic value of amodiaquine when used in combination with artesunate or another antiviral. Twit Text FOAVip In Vivo Activity of Amodiaquine against Ebola Virus Infection ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=31882748 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=31882748 #FOAvip English Wikipedia <ref>{{Cite pmid|31882748}}</ref> In Vivo Activity of Amodiaquine against Ebola Virus Infection #MMPMID31882748 DeWald LE; Johnson JC; Gerhardt DM; Torzewski LM; Postnikova E; Honko AN; Janosko K; Huzella L; Dowling WE; Eakin AE; Osborn BL; Gahagen J; Tang L; Green CE; Mirsalis JC; Holbrook MR; Jahrling PB; Dyall J; Hensley LE Sci Rep 2019[Dec]; 9 (1): 20199 PMID31882748show ga During the Ebola virus disease (EVD) epidemic in Western Africa (2013?2016), antimalarial treatment was administered to EVD patients due to the high coexisting malaria burden in accordance with World Health Organization guidelines. In an Ebola treatment center in Liberia, EVD patients receiving the combination antimalarial artesunate-amodiaquine had a lower risk of death compared to those treated with artemether-lumefantrine. As artemether and artesunate are derivatives of artemisinin, the beneficial anti-Ebola virus (EBOV) effect observed could possibly be attributed to the change from lumefantrine to amodiaquine. Amodiaquine is a widely used antimalarial in the countries that experience outbreaks of EVD and, therefore, holds promise as an approved drug that could be repurposed for treating EBOV infections. We investigated the potential anti-EBOV effect of amodiaquine in a well-characterized nonhuman primate model of EVD. Using a similar 3-day antimalarial dosing strategy as for human patients, plasma concentrations of amodiaquine in healthy animals were similar to those found in humans. However, the treatment regimen did not result in a survival benefit or decrease of disease signs in EBOV-infected animals. While amodiaquine on its own failed to demonstrate efficacy, we cannot exclude potential therapeutic value of amodiaquine when used in combination with artesunate or another antiviral. |Amodiaquine/*therapeutic use[MESH] |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH] |Artemisinins/*therapeutic use[MESH] |Disease Models, Animal[MESH] |Drug Combinations[MESH] |Female[MESH] |Hemorrhagic Fever, Ebola/*drug therapy[MESH] |Macaca mulatta[MESH]In Vivo Activity of Amodiaquine against Ebola Virus Infection (epmc).pdf DeepDyve Pubget Overpricing